2025 United Kingdom Antibody Library Technology Market Revenue Opportunities Report
Description
The 2025 United Kingdom Antibody Library Technology Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibody Library Technology Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively involved in the Antibody Library Technology Market in the United Kingdom include Cambridge Antibody Technology (CAT), RxBiologics, Abcam plc, and Kymab. CAT, based in Cambridge, was a pioneering biotech firm specializing in antibody therapeutics via phage display technology and was acquired by AstraZeneca, forming part of MedImmune's biologics R&D division. RxBiologics, part of the RxCelerate Group, offers antibody discovery services using its proprietary Galaxy® library platform emphasizing fully human, stable antibodies designed for therapeutic development, with a flexible client-focused approach. Abcam plc, headquartered in the UK, is a major player profiled globally for its antibody technology platforms, contributing to the UK biotech ecosystem. Kymab, also UK-based, developed novel therapeutics and vaccines from human antibody libraries, spun out from the Wellcome Sanger Institute, and was acquired by Sanofi in 2021 after raising significant funding to advance antibody medicines for cancer and autoimmune diseases.
These companies represent a blend of established and innovative players leveraging diverse antibody library platforms, including phage display, mammalian display, and genetic engineering of antibody genes. Cambridge Antibody Technology’s contributions include the discovery of blockbuster drugs like Humira and Benlysta through their display technology, underscoring their impact on global antibody therapeutics. RxBiologics and Abcam focus on providing advanced antibody libraries and discovery platforms that facilitate rapid biologic drug development and precision medicine solutions. Kymab’s approach capitalized on human genome science and chromosome engineering to create high-quality human antibodies addressing immune system modulation. Collectively, these firms support the UK’s leading position in antibody library research, therapeutic antibody development, and personalized medicine innovation.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibody Library Technology Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively involved in the Antibody Library Technology Market in the United Kingdom include Cambridge Antibody Technology (CAT), RxBiologics, Abcam plc, and Kymab. CAT, based in Cambridge, was a pioneering biotech firm specializing in antibody therapeutics via phage display technology and was acquired by AstraZeneca, forming part of MedImmune's biologics R&D division. RxBiologics, part of the RxCelerate Group, offers antibody discovery services using its proprietary Galaxy® library platform emphasizing fully human, stable antibodies designed for therapeutic development, with a flexible client-focused approach. Abcam plc, headquartered in the UK, is a major player profiled globally for its antibody technology platforms, contributing to the UK biotech ecosystem. Kymab, also UK-based, developed novel therapeutics and vaccines from human antibody libraries, spun out from the Wellcome Sanger Institute, and was acquired by Sanofi in 2021 after raising significant funding to advance antibody medicines for cancer and autoimmune diseases.
These companies represent a blend of established and innovative players leveraging diverse antibody library platforms, including phage display, mammalian display, and genetic engineering of antibody genes. Cambridge Antibody Technology’s contributions include the discovery of blockbuster drugs like Humira and Benlysta through their display technology, underscoring their impact on global antibody therapeutics. RxBiologics and Abcam focus on providing advanced antibody libraries and discovery platforms that facilitate rapid biologic drug development and precision medicine solutions. Kymab’s approach capitalized on human genome science and chromosome engineering to create high-quality human antibodies addressing immune system modulation. Collectively, these firms support the UK’s leading position in antibody library research, therapeutic antibody development, and personalized medicine innovation.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
